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Clinical prognosis of metastasized colorectal carcinoma (CRC) is still not at desired levels and novel drugs are needed.
Here, we focused on the multi-tyrosine kinase inhibitor E7080 (Lenvatinib) and assessed its therapeutic efficacy against
human CRC cell lines in vitro and human CRC xenografts in vivo. The effect of E7080 on cell viability was examined on 10
humanCRCcell linesandhumanendothelial cells (HUVEC). The inhibitory effect of E7080onVEGF-inducedangiogenesis
was studied in an ex vivo mouse aortic ring angiogenesis assay. In addition, the efficacy of E7080 against xenografts
derived fromCRCcell lines andCRCpatient resection specimenswithmutated KRASwas investigated in vivo. A relatively
lowcytotoxic effect of E7080onCRCcell viabilitywas observed in vitro. Endothelial cells (HUVEC)weremore susceptible
to the incubation with E7080. This is in line with the observation that E7080 demonstrated an anti-angiogenic effect
in a three-dimensional ex vivo mouse aortic ring angiogenesis assay. E7080 effectively disrupted CRC cell-mediated
VEGF-stimulated growth of HUVEC in vitro. Daily in vivo treatment with E7080 (5mg/kg) significantly delayed the growth
of KRAS mutated CRC xenografts with decreased density of tumor-associated vessel formations and without tumor
regression. This observation is in linewith results that E7080 did not significantly reduce the number of Ki67-positive cells
in CRC xenografts. The results suggest antiangiogenic activity of E7080 at a dosage thatwaswell tolerated by nudemice.
E7080 may provide therapeutic benefits in the treatment of CRC with mutated KRAS.
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Table 1. Effect of E7080 on cell viability of human CRC cells and human umbilical vein
endothelial cells (HUVEC).
IC50 values were determined following E7080 treatment for 72 hours in media with low serum (1% (v/v)
FCS). Cell lines are arranged according to increasing IC50 values. Shown are the results as mean and 95%
confidence interval (CI) of IC50 of at least three independent proliferation assays with hexaplicates. IC50
values and 95% CI were determined using GraphPad Prism software. See also Fig. 1A.Wild-type (wt) KRAS
and mutated (mut) KRAS were determined with Sanger Catalogue of somatic mutations in cancer
(COSMIC) database.
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/).
Cell lines KRAS status IC50 (μmol/l) 95% CI (μmol/l)
CaCo2 wt N1000 ¯¯¯¯
Colo741 wt N1000 ¯¯¯¯
SW620 mut 548 273-111
HT29 mut 431 299-620
HCT116 mut 399 296-538
T84 mut 276 179-427
SW480 mut 240 183-313
Colo678 wt 222 175-283
LS174T mut 144 96-215
HCT15 mut 120 91-158
HUVEC wt 22 14-36
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Colorectal carcinoma (CRC) is the most common malignancy of
the gastrointestinal tract and constitutes approximately 15% of all
cases of cancer. Despite multiple advances in diagnosis and treatment
of CRC, approximately 45% of patients with CRC experience
local recurrence and/or metastases with a consequent dramatic decline
in prognosis. In the industrialized West, CRC is therefore, the third
most common cause of death from cancer [1].
Metastases of CRC are localized in the liver in 40% to 80% of
patients. The principal curative treatment option is surgical resection,
although only one fourth of patients with colorectal liver metastases
are primary operable [2]. Due to this fact, in daily clinical situations,
patients are stratified into three groups: patients with resectable liver
metastases who are treated by curative surgery, patients with
resectable liver metastases after a neoadjuvant therapy undergoing
surgical resection at a later date, and patients with wide-spread and
unresectable metastases even after downsizing chemotherapy. In
recent years marked improvements have been made in the medial
treatment of patients with CRC metastasis. Angiogenesis is essential
for solid tumor growth and anti-angiogenic therapy may offer an
additional treatment option at this stage [3]. New cytostatic agents
and antibodies targeting epidermal growth factor receptor (EGFR) on
the cancer cell surface and vascular epithelial growth factor (VEGF)
released by cancer cells [4] have increased median survival of patients
with advanced CRC to more than 2 years, almost doubling the
survival time of the 5-Fluorouracil (5-FU) era [5,6].
One promising mechanism to inhibit tumor growth or induce
tumor shrinking in combination with classical chemotherapy is the
use of VEGF signaling inhibitors. The recombinant humanized
monoclonal antibody bevacizumab is directed against the pro-
angiogenic VEGF subgroup A. It has been approved, in combination
with chemotherapy, for the treatment of colorectal liver metastasis
with mutations in the Kirsten Ras (KRAS) oncogene, coding for a
cytoplasmic GTP-binding protein [7,8]. The KRAS oncogene is
mutated in approximately 35% to 45% of CRC [9]. Bevacizumab
binds to VEGF and inhibits VEGF receptor binding, thereby
preventing the growth and maintenance of tumor blood vessels.
Bevacizumab in combination with 5-FU based chemotherapy has
shown a survival benefit compared to control groups in several trials
[10], whereas bevacizumab alone does not improve patient survival
[11] and its application is limited by adverse drug effects [12]. One
explanation for the failure of bevacizumab monotherapy to induce
enduring clinical responses may be the fact that bevacizumab targets
VEGF-A exclusively, thus only one member of a large family of pro-
angiogenic growth factors inducing angiogenesis is targeted. This
would suggest that the blockage of the interaction of multiple growth
factors with their receptors might improve therapeutic efficacy [13].
For example, regorafenib, a novel oral multi-kinase inhibitor targeting
VEGF receptor (VEGFR) and a broad range of other receptor
tyrosine kinases (RTK) including BRAF, demonstrates superior
effects over monoclonal antibodies targeting VEGF only [14]. A
regorafenib monotherapy was recently approved for an international,
multicenter, randomized, placebo-controlled, phase 3 trial. Regorafenib
increased the survival of patients with chemorefractory metastatic
colorectal cancer to 1.4 months compared to a placebo group with
progressive cancer after all standard therapies [15]. In conclusion,
targeting a broad range of RTK seems to have advantages over targeting
RTK ligands only. Lenvatinib (E7080) is an orally active multi-kinase
inhibitor of VEGFR2 and VEGFR3 with IC50 values of 4 nmol/l and5.2 nmol/l, respectively. In addition, E7080 also inhibits VEGFR1,
fibroblast growth factor receptor (FGFR1), and platelet-derived growth
factor receptor (PDGFR) with IC50 of 22 nmol/l, 46 nmol/l and
51 nmol/l [16]. Lenvatinib is also reported to have inhibitory activity to
RET (rearranged during transfection) kinase [17], a receptor for growth
factors of the glial-derived neurotrophic factor family. Lenvatinib is
currently in a phase 2 study with KIF5B-RET-positive adenocarcinoma
of the lung (Clinical Trials.gov; NCT01877083). E7080 shows potent
antitumor effects in xenograft models of various cancer types, such as
breast and lung cancer, pleura mesothelioma or sarcoma [18–20].
The aim of the present study was to evaluate a) the efficacy of E7080
(Lenvatinib) on a broad range of human CRC cell lines and primary
human endothelial cells (HUVEC) in vitro, b) the anti-angiogenic
effect of E7080 in a three-dimensional ex vivo mouse aortic ring
angiogenesis assay, and c) the therapeutic efficacy of E7080 against
xenografts derived from CRC cell lines and CRC patient resection
specimens with mutated KRAS in vivo.
Materials and Methods
Cell Lines
Human CRC cells (Table 1) were routinely cultured in their
recommended media supplemented with 10% (v/v) heat-inactivated
fetal calf serum (FCS), 2 mmol/l glutamine (Invitrogen), 100 U/ml
penicillin, and 100 μg/ml streptomycin. Cancer cell lines were obtained
from the American Type Culture Collection (www.atcc.org) with
exception ofHCT116 andHT29 (Leibniz Institute, GermanCollection
of Microorganisms and Cell Cultures, Braunschweig, Germany),
SW620 (European Collection of Cell Cultures, Salisbury, UK) and
WiDr (Cell Lines Service, Eppenheim, Germany). Human umbilical
vein endothelial cells (HUVEC) were obtained from PromoCell
(Heidelberg, Germany) and cultured according to the manufacturer's
recommendations in endothelial growth medium (PromoCell).
Human CRC Xenografts from Patient Primary
Resection Specimens
Low-passage CRC xenografts HROC71 (T2M1) were established
from primary resection specimens of a patient with Lynch syndrome
[21]. For this, tumor samples were subcutaneously transplanted into
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(3 × 3 × 3 mm) and stored in liquid nitrogen.
Reagents
Lenvatinib (E7080) was obtained from Selleckchem (Boston, USA).
Stock solutions for in vitro (1 mmol/l) and in vivo (5,9 mmol/l) studies
were prepared with phosphate buffered saline (PBS; Gibco, Life
Technologies GmbH, Darmstadt, Germany) with 10% DMSO (final
concentration; Sigma Aldrich) and aliquots were stored at −20 °C. The
stock solutionwas further diluted for in vitro and in vivo studies. The final
concentration ofDMSOwas ≤1% in all assays, with andwithout E7080.
Western Blotting
Cultured cells were rinsed three times with ice-cold PBS, harvested,
and lysed directly in RIPA buffer (Pierce, Thermo Scientific, Rockford,
USA) for immunoblot analysis. Cell debris was removed by
centrifugation at 15,000g for 10 minutes at 4°C. The supernatant
was used as total protein lysate. For each sample, 10 μg of total protein
lysate was subjected to 10% sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS page), followed by immunoblot analysis.
Immunoblots were probed with antibodies against MYC (Y69,
#ab32072; Abcam, Cambridge, UK), GAPDH (#G9295, Sigma
Aldrich GmbH, München, Germany), Vinculin (hVIN-1, #9131,
Sigma Aldrich GmbH), pERK1/2T202/T204 (#9101, Cell Signaling
Technology, Danvers, MA, USA), and ERK1/2 (C14, #SC-154, Santa
Cruz Biotechnology, USA). All antibodies were used according to the
manufacturer’s instructions. The results were visualized with secondary
antibodies (GE Healthcare Life Sciences Europe, Freiburg, Germany)
against mouse (NA9310) or rabbit (NA9340) primary antibodies
combined with enhanced chemiluminescence (ECL) western blotting
substrates (Pierce, Thermo Scientific).
Immunostaining
Following excision, tumors were snap frozen in liquid nitrogen and
subsequently stored at −80°C. Sections were used for staining towards
CD31, CD34, Ki67 and CAIX using standard procedures [22].
The following antibodies, diluted in a commercial antibody diluent
(DAKO, Hamburg, Germany), were used: anti-Ki-67 antigen (clone
MIB-1,DAKO), final dilution 1:25; anti-CD31 (clone SZ31,DAKO),
final dilution 1:100; anti-CD34 (clone MEC14.7, Linaris,
Dossenheim, Germany), final dilution 1:200 and anti-carbonic
anhydrase 9 (CA9, CAIX, clone GT12, GeneTex, Irvine, USA), final
dilution 1:500. After incubation with the primary antibody for 1 hour
at room temperature, the slides were washed in PBS and incubated with
the following secondary antibodies: goat anti-mouse-HRP (DAKO),
final dilution 1:100 or rabbit anti-rat-HRP (DAKO), final dilution
1:100. After development in 5% 3,3′-diaminobenzidine (DAKO) and
counterstaining with haematoxilin, the sections were dehydrated in
graded ethanol and embedded in Vitro Clud (Langenbrinck,
Emmendingen, Germany). Stained slides were photographed at 20x
magnification with a Keyence Biorevo BZ-9000 Microscope (Keyence
Corporation, Osaka, Japan) applying Z-stack technology to improve
the quality of images. The number of stained cells per section was
quantified by using measurement module BZ-H3C (Hybrid Cell
Count Vers.1.1, Keyence).Aortic Ring Assay
The thoracic aortae from C57BL/6 mice (8 weeks) were isolated and
subsequently cut into 1 mm thick rings after removal of adventitial fat.In two steps the aortic rings were then embedded in 48-well plates
between two layers of 200 μl collagen gel, containing collagen type 1
(Purecol, CellSystems, Germany), sodium hydroxide, L-glutamine,
sodium pyruvate, sodium bicarbonate, MEM (10×), penicillin-
streptomycin and dH2O. First, the aortic rings were set on the first
layer after polymerization of the gel. Then, the rings were covered with
the second gel layer and after polymerization cultivated in 300 μl
DMEM (10% FCS, 1% penicillin-streptomycin) at 37°C and 5%
CO2. Some of the rings were treated with VEGF (50 ng/ml) or E7080
(1 μmol/l and 10 μmol/l), or with a combination of both. The medium
was changed every third day. A phase contrast microscope (Leica,
Germany) equipped with a digital camera (Leica, Germany) was used
for evaluation and documentation of the aortic rings.
CRC Xenograft Studies
To generate CRC xenografts, 2.5 × 106 HCT116 cells, or LS174T
cells resuspended in 100 μl phosphate-buffered saline were injected
subcutaneously into the left hind flank of athymic female NMRI-
Foxn1nu (nude) mice aged 8 to 10 weeks with 24 to 27 g body weight
(Janvier, Le Genest-Saint-Isle, France). Subcutaneous CRC xenograft
implantation was performed as described previously [23]. Tumors
were measured using calipers and tumor volume VT (mm
3) was
calculated using the ellipsoid formula A2 x B x π/6, where A
represents the smaller diameter [22]. Endpoint for the experiments
was attainment of a tumour volume between 600 and 700 mm3
(target tumor volume) or within 6 weeks, when arrest of tumor
growth was observed. When tumors reached a volume of 40 to 60
mm3, mice were randomized into therapy and control groups. Mice
in therapy groups were treated daily with 5 mg/kg E7080 by oral
gavage until tumors of control group reached target tumor volume.
Tumour size and body weight of all animals were measured every day.
All animal experiments were authorized by the local ethics committee,
and mice were treated according to institutional and European
Union guidelines.
Blood Count and Clinical Chemistry
Blood counts (erythrocytes, leukocytes, thrombocytes), the
amount of hemoglobin, and the activity of liver enzymes alanine
transaminase (ALT) and aspartate transaminase (AST) were
measured at the central laboratory of the University Hospital
of Würzburg.
Detection of VEGF Production
One million CRC cells and HUVEC were cultured in 6-well plates
with serum-reduced (1%)RPMI 1640medium for 48 hours. Afterwards,
supernatant were harvested, centrifuged and stored at -80 °C. VEGF
concentration was assayed by ELISA according to manufacturer’s
instructions (R&D Systems GmbH, Germany). All samples were run
in triplicate and each assay was conducted 2 times independently.
Proliferation Assay
WST-8 is reduced by cellular dehydrogenases to an orange
formazan product that is soluble in tissue culture medium. The
amount of formazan produced is directly proportional to the number
of living cells. Cells (CRC cell lines and HUVEC) were seeded in 96-
well flat-bottom plates at 5 × 103 cells per well with 100 μl RPMI
1640 medium supplemented with 1% (v/v) FCS, 2 mmol/l
glutamine (Invitrogen, Darmstadt, Germany) and antibiotics
(100 IU/ml penicillin, and 1 μg/ml streptomycin). The assays were
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The cells were cultured to reach the 50%-60% confluence on
the second day when treated with serial dilutions of E7080
as indicated or supernatant. The assays were cultured at 37 °C in
a humidified atmosphere of 5% CO2 in air for 3 days.
Subsequently, cell viability was determined by WST-8 assay
according to manufacturer’s instructions (PromoCell GmbH,
Heidelberg, Germany).
Statistical Analysis
All graphs and statistical analyses were made using Prism 5 statistical
software (GraphPad Software, Inc, La Jolla, CA, USA). IC50 values were
calculated with nonlinear regression fit to a sigmoidal dose-response
curve (variable slope). Values for tumor volume and body weight were
compared with two-way ANOVA with Bonferroni post hoc tests. One-
way ANOVA was performed for comparison between different groups.
Differences were considered statistically significant at a P value of less
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Human Endothelial Cells are More Susceptible to E7080 than
CRC Cells
The effect of E7080 on cell viability was examined on 10 human CRC
cell lines harboring wildtype or mutated KRAS (Table 1) and human
umbilical endothelial cells (HUVEC) using the cell viability test WST8.
Dose response analysis showed that VEGF stimulated HUVEC were 5
times more susceptible to the incubation with E7080 (IC50: 22 μmol/l)
thanCRC cell lineHCT15 (KRASmutated) with IC50 value of 120μmol/l,
the lowest of the tested CRC cell lines (Figure 1A, Table 1). E7080 had less
effect on cell viability ofCaCo2 (KRASwildtype), Colo741 (KRASwildtype),
SW620 (KRASmutated) andHT29 (KRASmutated) cells. The IC50 values
ranged betweenN1000μmol/l for CaCo2 andColo741 and 431μmol/l for
HT29. Colo678 with wildtypeKRASwasmore susceptible to E7080 (IC50:
222μmol/l) thanCaCo2 andColo741 (both withwildtypeKRAS). It seems
that E7080 did not demonstrate a strong cytotoxic effect on human CRC
cells in comparison to HUVEC.E7080 (1 µmol/l)
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E7080 is supposed to inhibit VEGF signaling, we analyzed the effect
of E7080 on cell viability of VEGF-stimulated HUVEC. For this,
serum starved HUVEC were stimulated with VEGF (20 ng/ml) and
treated with increased levels of E7080 (0.001-100 μmol/l). VEGF-
induced cell growth was prevented already at 0.001 μmol/l E7080
and cytotoxic effects were observed at levels of 1.0 μmol/l E7080
(Figure 1B).
It has been hypothesized that the multi-kinase inhibitor E7080
inhibits several receptor tyrosine kinases (RTK) such as VEGF-,
PDGF receptors and cKIT. One of the major downstream signaling
pathways of these RTK is supposed to be the mitogen-activated
protein kinase (MAPK) pathway. HUVEC were serum starved
overnight and then stimulated with VEGF (20 ng/ml) in
combination with different concentrations of E7080 (0.1 to 100
μmol/l). Addition of VEGF to starved HUVEC led to a pronounced
induction of MAPK activity after 5 minutes, shown by induced
phosphorylation of extracellular signal regulated kinase (ERK1/2).
E7080 inhibits VEGF-induced stimulation of MAPK signaling
pathway (Figure 1C). Since MAPK up-regulates the cell proliferation
promoting transcription factor MYC, we analyzed the effect of E7080
on MYC expression in VEGF-stimulated HUVEC. For this, we
stimulated serum starved HUVEC with VEGF for 8, 16, 24 and 36
hours in the presence or absence of E7080. VEGF leads to an up-
regulation of MYC after 8 hours, which was nearly completely
abrogated by addition of E7080 (Figure 1D).
E7080 Inhibits Micro Vessel Sprouting in a Three-Dimensional
Ex Vivo Mouse Aortic Ring Angiogenesis Assay
The inhibitory effect of E7080 on VEGF-induced angiogenesis
was studied in a three-dimensional ex vivo mouse aortic ring
angiogenesis assay. The micro vessel sprouting from aortic rings
embedded in collagen was stimulated by VEGF (50 ng/ml), leading
to a network of vessels around the aortic rings after 11 days. In
contrast, the presence of E7080 (1 μmol/l and 10 μmol/l) reduced the
VEGF-induced sprouting in a dose-dependent manner (Figure 2).
CRC Cells Produce High Levels of VEGF and Express
VEGF Receptors
VEGF receptor (VEGFR) expression of CRC cell lines
and HUVEC were proved on both mRNA and protein levels.
HUVEC and CRC cell lines expressed mRNA of all three VEGFR
(Supplementary Figure 1A). In addition, VEGFR 1 and 3 protein
expression in all CRC cell lines and HUVEC were demonstrated by
immunohistochemical staining (Supplementary Figure 1B). VEGF
protein expression was determined in supernatant of CRC cells
cultured for 24 hours. All CRC cells secreted large amounts of VEGF
without any stimulation. In comparison to CRC cells, no VEGF
protein could be determined in supernatant of HUVEC cultures
(Figure 3A). To check if E7080 could interrupt the VEGF-mediated
interaction between CRC cells and HUVEC, serum starved HUVEC
were stimulated with CRC cell supernatant, either with or without
E7080 (1 μmol/l) for 24 hours. CRC cell supernatant stimulated
HUVEC proliferation, whereas the presence of E7080 prevented the
growth induction of HUVEC (Figure 3B, Supplementary Figure 2).E7080 Delays Growth of CRC Xenografts
The antitumor effect of E7080 was analyzed for human CRC
xenografts in nude mice. Subcutaneous implantation of 2.5 × 106HCT116 or LS174T cells into nude mice has been shown to induce
reproducible tumor development within 7 to 10 days. Mice were
randomized into a control group treated with saline and an
intervention group treated with E7080 when tumors reached a
volume of 40-60 mm3. The intervention group received a daily
dosage of 5 mg/kg E7080. After 8 to 10 days, tumors of E7080
treated animals demonstrated a significant delay in tumor growth
(Figure 4, A and B). E7080 slowed tumor growth but did not cause
tumor regression. The experiments were stopped when tumors of
control mice reached a tumor volume of 600-800 mm3. Then,
tumors were explanted for in vitro evaluation. The volume of E7080
treated HCT116 and LS174T tumors at the end of experiment
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between E7080 treated and untreated tumor) between 66 and 72% in
comparison to untreated tumors of control animals.
The effect of E7080 on human CRC xenografts established from
primary resection specimens with mutated KRAS was also analyzed in
nude mice. Equal amounts of primary CRC samples (one xenograft
cube with 3 × 3 × 3 mm) were implanted subcutaneously into nude
mice. The growth rate of CRC xenograft samples was much lower
compared to xenografts established by HCT116 and LS174T cells.
After 36 days of E7080 treatment, a significant difference in tumor
growth between E7080 treated and untreated animals was observed.
The E7080 induced growth reduction at the end of experiment was
62% (Figure 4C).
The daily application of 5 mg/kg E7080 was well tolerated by the
animals without treatment-associated lethality and adverse events such
as loss of body weight (Figure 4,D–F). In addition, no differences were
observed in liver enzyme activity (Figure 4G), white and red blood
count, thrombocytes, and hemoglobin (Figure 4H).
E7080 induces hypoxic conditions in CRC tumors by
inhibition of angiogenesis without reduction of
Ki67-positive tumor cells
Control and E7080 treated tumors showed central necrosis
areas without significant differences in size (data not shown). There
was no reduction in the number of Ki67-positive cells in the viable
part of tumors in both E7080 treated mice and untreated mice
(Figure 5A). E7080 is supposed to inhibit VEGF signaling between
tumor cells and endothelial cells within stromal microenvironment
and therefore, we evaluated the effect of E7080 on angiogenesis. The
CD31 and CD34 staining results showed that E7080 significantly
decreased micro vessel density (Figure 5, B and C). A qualitative
reduction in vascularity was also observed in primary tumor samples
of E7080 treated mice (Supplementary Figure 3). The decreasedmicro vessel density leads to an insufficient supply with oxygen and,
increasing hypoxic conditions within the tumor. Staining with the
hypoxia marker carbonic anhydrase 9 (CA9, CAIX) revealed increased
areas of hypoxia in tumors of E7080 treated mice (Figure 5, B and C;
Supplementary Figure 3). These results indicate that E7080 effectively
inhibits angiogenesis in vivo and therefore, delays the growth of
CRC tumors.
Discussion
In this study we show that the multiple kinase inhibitor, E7080,
effectively delays the growth of human CRC xenografts from both
HCT116 and LS174T cells (KRAS mutated), respectively, and from
primary resection specimens with mutated KRAS in nude mice. The
presented in vivo and in vitro data suggest that E7080 suppresses
capillary sprouting and inhibits endothelial cell proliferation.
The anti-angiogenic effect of E7080 was also observed in a three-
dimensional ex vivo mouse aortic ring angiogenesis assay. In addition,
the therapy with E7080 in vivo decreased the density of tumor-
associated vessel formations that leads to an increase of hypoxic areas
within CRC xenografts. Conclusively, these data suggest that the
major mechanism by which E7080 interferes with solid tumor growth
is apparently the inhibition of angiogenesis, essential for supplying the
tumor with oxygen and nutrients.
In the present study we also show that E7080 demonstrates different
cytotoxic effects on human CRC cells in vitro. The IC50 values for the
10CRC cell lines tested ranged between 120μmol/l undN1000μmol/l
(Table 1). It is important to emphasize that in vitro assays to determine
IC50 values depend to a significant degree on a number of factors,
including cell viability, cell proliferation rates, cell confluency at the
time of drug exposure and method used to determine cell viability
(type of assay). This may explain why IC50 values for certain tumor cell
lines can differ [24,25]. Nevertheless, with this panel of CRC cell lines
we demonstrate a relatively low cytotoxic effect of E7080 on CRC cell
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Figure 4. E7080 retards tumor growth in vivo without adverse events.Xenografts of LS174T (A), HCT116 (B) and patient resection
specimens (C). Nude mice received daily 5 mg/kg E7080 orally or vehicle control. (D-F) Body weight was monitored throughout
the indicated period. At the end of experiment the activity of liver enzymes alanine transaminase, AST, and aspartate transaminase,
ALT (G) and blood parameters (H) were estimated. Values represent means with bars indicating standard errors. *P b 0.05, **P b 0.01,
***P b 0.001 to untreated control.
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of endothelial cells described here was also shown by others [26].
The ability to induce and sustain tumor vascularization by
angiogenesis is a hallmark of cancer [27] that correlates with
advanced-stage disease and poor prognosis [28]. Solid tumors go
through a prolonged state of avascularity in which they are supplied
with oxygen and nutrients by simple passive diffusion up to a size of
2 to 4 mm in diameter [29]. Starting from this size, growth and
survival of solid tumors require vascularization through angiogenesis
and postnatal vasculogenesis [30]. The new blood vessels secure the
supply of oxygen and nutrition [29,31]. Tumor cells secrete
numerous growth factors such as VEGF, which is known to be one
of the major pro-angiogenic factors [4,32]. VEGF stimulates both the
proliferation and migration of endothelial cells leading to new vessel
formation [33]. In tumor cells, VEGF signalling affects tumor
function independently of angiogenesis [4]. Our data show that the
cells lines used here produce VEGF, which induces the growth of
human endothelial cells including HUVEC. The VEGF-induced
growth of HUVEC was inhibited by low dose E7080 (0.1 μmol/l).
CRC cell lines were relatively resistant to the treatment with E7080
in vitro and the E7080 concentration, which was toxic for HUVEC
(IC50: 22 μmol/l), did not influence CRC cell viability. HUVECtreated with low dose E7080 (10 μmol/l) demonstrated a dramatic
inhibition of cell viability by blocking the induction of VEGFR-
mediated downstream MAPK signaling. In this respect, our results
are in line with previous reports [26]. Furthermore, our data show a
dramatic reduction of MYC up-regulation in HUVEC by E7080
after VEGF stimulation. MYC is a helix-loop-helix leucine zipper
transcription factor and is one of the major downstream targets of the
active MAPK-signaling pathway. VEGF has been demonstrated to
induce MYC expression in human endothelial cells [34,35] and up-
regulation of MYC in turn has been shown to lead to cell
proliferation [36].
The present results of CD31 and CD34 staining show that E7080
significantly decreases the tumor micro vessel density, which might
prevent exponential tumor growth by limiting the tumor supply with
essential oxygen and nutrients. The undersupply with oxygen in turn
increases hypoxic conditions within the tumor. Staining with the
hypoxia marker carbonic anhydrase 9 [37] revealed an increase in
hypoxic areas within solid tumors grown in E7080-treated mice.
Carbonic anhydrase 9 is a hypoxia-inducible protein that regulates
cellular pH to promote cancer cell survival and invasion in hypoxic
microenvironments. It is also a biomarker of poor prognosis for breast
cancer metastasis and patient survival [38]. It is well known, that
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Figure 5. The E7080-mediated influence of microvascularization induces tumor hypoxia. (A) Representative immunohistochemical
staining of untreated and E7080 treated tumors (LS174T). Quantitative analysis of LS174T derived xenografts (B) and HCT116 derived
xenografts (C), both KRAS mutated. Tumor sections were stained towards Ki67, CD31, CD34, and CAIX (carbonic anhydrase 9) using
standard immunohistochemical procedures as described in Material andMethods. Results are shown as Tukey boxplot with first, second
(the median) and third quartiles of four to seven animals (Figure 4) per group. The lower whisker represents the 1.5 interquartile
range (IQR) of the lower quartile, and the top whisker represents the 1.5 IQR of the upper quartile. The point indicates an outlier. *P b 0.05,
**P b 0.01, ***P b 0.001 to control tumors. For the results of CRC xenografts derived from patient resection specimens with KRAS
mutation see Supplementary Figure 3.
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regulation of glycolysis with excessive oxygen-independent glucose
degradation [39,40]. The basis of this adaption is the up-regulation
of glycolytic enzymes mediated by hypoxia-inducible factor 1α (HIF-
1α) and proto-oncogenes like KRAS and MYC or tumor suppressor
genes like p53 [39,41].
CRC is one of the most common cancers and accounts for about
500,000 deaths worldwide every year [1]. Whereas a five-year survival
rate of 90% for local limited CRC without lymph node metastasis is
relatively good, prognosis drops to less than 10% in the case of distant
metastasis. A combination of chemotherapy and a targeted therapy
directed against VEGF or EGFR is presently used for metastatic
CRC, either as palliative or neoadjuvant therapy [42]. Currently,
KRAS mutation status of CRC is used to predict the outcome for
treatment with monoclonal antibodies. Patients with CRC harboring
wild-type KRAS may benefit from anti-EGFR antibody therapy with
Cetuximab [43], whereas patients with KRAS mutated CRC are
currently treated with the anti-VEGF antibody Bevacizumab in
combination with chemotherapy. Nevertheless, the therapeutic
options for patients with KRAS mutated CRC are limited.First, the treatment duration for classic chemotherapeutics is
restricted due to cumulative dosage toxicity. Second, addition of
Bevacizumab to classic chemotherapy has only a small positive effect.
Third, Bevacizumab has to be administered intravenously, making it
impractical for maintenance therapy. Therefore, new therapeutic
agents are needed to improve the survival of this patient group.
E7080 is currently under evaluation in several clinical trials
[16,44–46]. Recently, the FDA approved the multi-kinase receptor
inhibitor Regorafenib for metastatic colorectal cancer [14]. In
comparison to Regorafenib, E7080 shows a more selective inhibition
profile for VEGFR2 and VEGFR3, whereas Regorafinib also inhibits
several members of the MAPK-signaling pathway, including
bRAFV600. With this ability, Regorafenib may also demonstrate a
direct inhibition of tumor growth rather than interfering with the
interaction between cancer cells and endothelial cells. The application
of Regorafenib is, however, limited due to adverse drug effects.
In summary, we have shown that E7080 (Lenvatinib), a multi-
tyrosine kinase inhibitor, suppresses in vivo angiogenesis at a dosage
of 5 mg/kg and delays the growth of xenografts with KRAS mutation.
These findings suggest a therapeutic potential of E7080 for treatment
980 E7080 (Lenvatinib) and colorectal cancer Neoplasia Vol. 16, No. 11, 2014of patients with KRAS mutated CRC that have no benefit from a first
line treatment with Cetuximab [43]. In addition, our findings implicate
the need to combine E7080 with chemotherapeutics such as FOLFOX
in future studies to further enhance its efficacy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.09.008.
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